In patients with transthyretin amyloid cardiomyopathy, the high-affinity TTR stabilizer, acoramidis, is associated with better clinical outcomes compared with placebo. Acoramidis is associated with ...

“The Andromeda study is the first comparing two contemporary regimens that shows a significant survival improvement for patients with AL amyloidosis,” said Kastritis, an associate professor at ...